These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37294090)

  • 61. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum.
    Liang D; Zhang G; Huang M; Wang L; Hong W; Li A; Liang Y; Wang T; Lu J; Ou M; Ren Z; Lu H; Zheng R; Cai X; Pan X; Xia J; Ke C
    Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558864
    [TBL] [Abstract][Full Text] [Related]  

  • 62. SARS-CoV-2 and immune-microbiome interactions: Lessons from respiratory viral infections.
    Cyprian F; Sohail MU; Abdelhafez I; Salman S; Attique Z; Kamareddine L; Al-Asmakh M
    Int J Infect Dis; 2021 Apr; 105():540-550. PubMed ID: 33610778
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lost microbes of COVID-19:
    Hazan S; Stollman N; Bozkurt HS; Dave S; Papoutsis AJ; Daniels J; Barrows BD; Quigley EM; Borody TJ
    BMJ Open Gastroenterol; 2022 Apr; 9(1):. PubMed ID: 35483736
    [TBL] [Abstract][Full Text] [Related]  

  • 64. SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021.
    Cohen C; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; du Plessis M; Carrim M; Buys A; Martinson NA; Kahn K; Tollman S; Lebina L; Wafawanaka F; du Toit J; Xavier Gómez-Olivé F; Dawood FS; Mkhencele T; Sun K; Viboud C; ; Tempia S
    medRxiv; 2021 Dec; ():. PubMed ID: 34909794
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.
    Gralinski LE; Sheahan TP; Morrison TE; Menachery VD; Jensen K; Leist SR; Whitmore A; Heise MT; Baric RS
    mBio; 2018 Oct; 9(5):. PubMed ID: 30301856
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study.
    Gottlieb M; Wang RC; Yu H; Spatz ES; Montoy JCC; Rodriguez RM; Chang AM; Elmore JG; Hannikainen PA; Hill M; Huebinger RM; Idris AH; Lin Z; Koo K; McDonald S; O'Laughlin KN; Plumb ID; Santangelo M; Saydah S; Willis M; Wisk LE; Venkatesh A; Stephens KA; Weinstein RA;
    Clin Infect Dis; 2023 Jun; 76(11):1930-1941. PubMed ID: 36705268
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice.
    Liu S; Selvaraj P; Sangare K; Luan B; Wang TT
    Cell Rep; 2022 Sep; 40(11):111359. PubMed ID: 36075211
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An Update on the Mutual Impact between SARS-CoV-2 Infection and Gut Microbiota.
    Li S; Zhou Y; Yan D; Wan Y
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016396
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
    Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
    Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
    Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
    J Virol; 2022 Sep; 96(17):e0096122. PubMed ID: 36000850
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differential Pathogenesis of SARS-CoV-2 Variants of Concern in Human ACE2-Expressing Mice.
    Natekar JP; Pathak H; Stone S; Kumari P; Sharma S; Auroni TT; Arora K; Rothan HA; Kumar M
    Viruses; 2022 May; 14(6):. PubMed ID: 35746611
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Profiles of gut microbiota associated with clinical outcomes in patients with different stages of SARS-CoV-2 infection.
    Krasaewes K; Chaiwarith R; Chattipakorn N; Chattipakorn SC
    Life Sci; 2023 Nov; 332():122136. PubMed ID: 37783267
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dissecting the role of the human microbiome in COVID-19 via metagenome-assembled genomes.
    Ke S; Weiss ST; Liu YY
    Nat Commun; 2022 Sep; 13(1):5235. PubMed ID: 36068270
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Analyze the clinical characteristics of mild and severe SARS-CoV-2 infected patients based on the local Omicron variant epidemic].
    Yan Y; Lyu C; Davgadorj C; Wang X; Sha M
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Jan; 35(1):32-36. PubMed ID: 36880235
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Relationship Between Pediatric Gut Microbiota and SARS-CoV-2 Infection.
    Romani L; Del Chierico F; Macari G; Pane S; Ristori MV; Guarrasi V; Gardini S; Pascucci GR; Cotugno N; Perno CF; Rossi P; Villani A; Bernardi S; Campana A; Palma P; Putignani L;
    Front Cell Infect Microbiol; 2022; 12():908492. PubMed ID: 35873161
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Gut and airway microbiota and their role in COVID-19 infection and pathogenesis: a scoping review.
    Liu TFD; Philippou E; Kolokotroni O; Siakallis G; Rahima K; Constantinou C
    Infection; 2022 Aug; 50(4):815-847. PubMed ID: 34671922
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Longitudinal alterations of the gut mycobiota and microbiota on COVID-19 severity.
    Maeda Y; Motooka D; Kawasaki T; Oki H; Noda Y; Adachi Y; Niitsu T; Okamoto S; Tanaka K; Fukushima K; Amiya S; Hara R; Oguro-Igashira E; Matsuki T; Hirata H; Takeda Y; Kida H; Kumanogoh A; Nakamura S; Takeda K
    BMC Infect Dis; 2022 Jun; 22(1):572. PubMed ID: 35751044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.